Abstract
Researchers in the field of T cell biology, pharmacology, molecular biology and genetic strategies have, over the past several years, systematically developed therapeutic approaches to tackle systemic and organ-specific autoimmune diseases, and treatment with general immunosupressants may soon be replaced by novel therapies based upon this research. Recently, interest in the field of regulatory T cells along with accumulated information that these cells play significant roles in preventing autoimmunity, may revolutionize the field of autoimmune disease therapy. Numerous research groups worldwide have combined forces to develop successful adoptive transfer methods so that regulatory T cells expanded in vivo or ex vivo, as antigen specific or polyclonal, can be used to treat autoimmune diseases. This chapter discusses the evolution of therapeutics for the treatment of autoimmune diseases with particular focus on regulatory T cell therapy using adoptive cell transfer and its treatment for graft-versus-host disease.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmunity Reviews 2003; 2:119–125
Sela M, Teitelbaum D. Glatiramer acetate in the treatment of multiple sclerosis. Expert Opinion on Pharmacotherapy 2001; 2:1149–1165
Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nature Reviews 2005; 4:510–518
Gonsette RE. Mitoxantrone immunotherapy in multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England) 1996; 1:329–332
Maini RN, Brennan FM, Williams R, et al. TNF-alpha in rheumatoid arthritis and prospects of anti-TNF therapy. Clinical and Experimental Rheumatology 1993; 11 Suppl 8:S173-S175
Shoda LK, Young DL, Ramanujan S, et al. A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity 2005; 23:115–126
Bielekova B, Goodwin B, Richert N, et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nature Medicine 2000; 6:1167–1175
Panitch HS, Hirsch RL, Haley AS, Johnson KP. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987; 1:893–895
Bartt RE. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy. Current Opinion in Neurology 2006; 19:341–349
Ransohoff RM. Natalizumab and PML. Nature Neuroscience 2005; 8:1275
Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. The New England Journal of Medicine 2006; 355: 1018–1028
Blanas E, Carbone FR, Allison J, Miller JF, Heath WR. Induction of autoimmune diabetes by oral administration of autoantigen. Science 1996; 274:1707–1709
Desquenne-Clark L, Esch TR, Otvos L, Jr., Heber-Katz E. T-cell receptor peptide immunization leads to enhanced and chronic experimental allergic encephalomyelitis. Proceedings of the National Academy of Sciences of the United States of America 1991; 88:7219–7223
Perrin PJ, Scott D, June CH, Racke MK. B7-mediated costimulation can either provoke or prevent clinical manifestations of experimental allergic encephalomyelitis. Immunologic Research 1995; 14:189–199
Robinson WH, Fontoura P, Lee BJ, et al. Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nature Biotechnology 2003; 21:1033–1039
Roffe E, Souza AL, Caetano BC, et al. A DNA vaccine encoding CCL4/MIP-1beta enhances myocarditis in experimental Trypanosoma cruzi infection in rats. Microbes and infection/Institut Pasteur 2006; 8:2745–2755
Miura K, Bowman ED, Simon R, et al. Laser capture microdissection and microarray expression analysis of lung adenocarcinoma reveals tobacco smoking- and prognosis-related molecular profiles. Cancer Research 2002; 62:3244–3250
Stosiek C, Garaschuk O, Holthoff K, Konnerth A. In vivo two-photon calcium imaging of neuronal networks. Proceedings of the National Academy of Sciences of the United States of America 2003; 100:7319–7324
Medh RD. Microarray-based expression profiling of normal and malignant immune cells. Endocrine Reviews 2002; 23:393–400
Rajan AJ, Gao YL, Raine CS, Brosnan CF. A pathogenic role for gamma delta T cells in relapsing-remitting experimental allergic encephalomyelitis in the SJL mouse. Journal of Immunology 1996; 157:941–949
El Behi M, Dubucquoi S, Lefranc D, et al. New insights into cell responses involved in experimental autoimmune encephalomyelitis and multiple sclerosis. Immunology Letters 2005; 96:11–26
Thorbecke GJ, Schwarcz R, Leu J, Huang C, Simmons WJ. Modulation by cytokines of induction of oral tolerance to type II collagen. Arthritis and Rheumatism 1999; 42:110–118
Maron R, Blogg NS, Polanski M, Hancock W, Weiner HL. Oral tolerance to insulin and the insulin B-chain: cell lines and cytokine patterns. Annals of the New York Academy of Sciences 1996; 778:346–357
Weiner HL, Mackin GA, Matsui M, et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 1993; 259:1321–1324
Blaha P, Bigenzahn S, Koporc Z, et al. The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockade. Blood 2003; 101:2886–2893
Khoury SJ, Hancock WW, Weiner HL. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain. The Journal of Experimental Medicine 1992; 176:1355–1364
Wekerle T, Kurtz J, Bigenzahn S, Takeuchi Y, Sykes M. Mechanisms of transplant tolerance induction using costimulatory blockade. Current Opinion in Immunology 2002; 14:592–600
Mor F. Preparation of lymphocytes for autolymphocyte therapy in metastatic renal carcinoma. Lancet 1990; 336:62
Ben-Nun A, Cohen IR. Vaccination against autoimmune encephalomyelitis (EAE): attenuated autoimmune T lymphocytes confer resistance to induction of active EAE but not to EAE mediated by the intact T lymphocyte line. European Journal of Immunology 1981; 11: 949–952
Vandenbark AA, Hashim G, Offner H. Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis. Nature 1989; 341: 541–544
Cohen IR, Quintana FJ, Mimran A. Tregs in T cell vaccination: exploring the regulation of regulation. The Journal of Clinical Investigation 2004; 114:1227–1232
Hellings N, Raus J, Stinissen P. T-cell vaccination in multiple sclerosis: update on clinical application and mode of action. Autoimmunity Reviews 2004; 3:267–275
Hafler DA, Cohen I, Benjamin DS, Weiner HL. T cell vaccination in multiple sclerosis: a preliminary report. Clinical Immunology and Immunopathology 1992; 62:307–313
Achiron A, Kishner I, Sarova-Pinhas I, et al. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Archives of Neurology 2004; 61:1515–1520
Tuohy VK, Mathisen PM. T cell design for therapy in autoimmune demyelinating disease. Journal of Neuroimmunology 2000; 107:226–232
Setoguchi K, Misaki Y, Araki Y, et al. Antigen-specific T cells transduced with IL-10 ameliorate experimentally induced arthritis without impairing the systemic immune response to the antigen. Journal of Immunology 2000; 165:5980–5986
Nakajima A, Seroogy CM, Sandora MR, et al. Antigen-specific T cell-mediated gene therapy in collagen-induced arthritis. The Journal of Clinical Investigation 2001; 107: 1293–1301
Rabinovich GA, Daly G, Dreja H, et al. Recombinant galectin-1 and its genetic delivery suppress collagen-induced arthritis via T cell apoptosis. The Journal of Experimental Medicine 1999; 190:385–398
Dreja H, Annenkov A, Chernajovsky Y. Soluble complement receptor 1 (CD35) delivered by retrovirally infected syngeneic cells or by naked DNA injection prevents the progression of collagen-induced arthritis. Arthritis and Rheumatism 2000; 43:1698–1709
Croxford B, Tham KW, Young A, Oreszczyn T, Wyon D. A study of local electrostatic filtration and main pre-filtration on airborne and surface dust levels in air-conditioned office premises. Indoor Air 2000; 10:170–177
Fiehn C, Wettschureck N, Krauthoff A, Haas R, Ho AD. Bone marrow-derived cells as carriers of recombinant immunomodulatory cytokine genes to lymphoid organs. Cancer Gene Therapy 2000; 7:1105–1112
Kim SH, Kim S, Evans CH, et al. Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4. Journal of Immunology 2001; 166:3499–3505
Morita Y, Yang J, Gupta R, et al. Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis. The Journal of Clinical Investigation 2001; 107: 1275–1284
Falqui L, Martinenghi S, Severini GM, et al. Reversal of diabetes in mice by implantation of human fibroblasts genetically engineered to release mature human insulin. Human Gene Therapy 1999; 10:1753–1762
Lee HC, Kim SJ, Kim KS, Shin HC, Yoon JW. Remission in models of type 1 diabetes by gene therapy using a single-chain insulin analogue. Nature 2000; 408:483–488
Woods JM, Katschke KJ, Volin MV, et al. IL-4 adenoviral gene therapy reduces inflammation, proinflammatory cytokines, vascularization, and bony destruction in rat adjuvant-induced arthritis. Journal of Immunology 2001; 166:1214–1222
Martino G, Furlan R, Brambilla E, et al. Cytokines and immunity in multiple sclerosis: the dual signal hypothesis. Journal of Neuroimmunology 2000; 109:3–9
Cottard V, Mulleman D, Bouille P, et al. Adeno-associated virus-mediated delivery of IL-4 prevents collagen-induced arthritis. Gene Therapy 2000; 7:1930–1939
Kim SH, Evans CH, Kim S, et al. Gene therapy for established murine collagen-induced arthritis by local and systemic adenovirus-mediated delivery of interleukin-4. Arthritis Research 2000; 2:293–302
Batteux F, Trebeden H, Charreire J, Chiocchia G. Curative treatment of experimental autoimmune thyroiditis by in vivo administration of plasmid DNA coding for interleukin-10. European Journal of Immunology 1999; 29:958–963
Koh JJ, Ko KS, Lee M, et al. Degradable polymeric carrier for the delivery of IL-10 plasmid DNA to prevent autoimmune insulitis of NOD mice. Gene Therapy 2000; 7:2099–2104
Lechman ER, Jaffurs D, Ghivizzani SC, et al. Direct adenoviral gene transfer of viral IL-10 to rabbit knees with experimental arthritis ameliorates disease in both injected and contralateral control knees. Journal of Immunology 1999; 163:2202–2208.
Whalen JD, Lechman EL, Carlos CA, et al. Adenoviral transfer of the viral IL-10 gene periarticularly to mouse paws suppresses development of collagen-induced arthritis in both injected and uninjected paws. Journal of Immunology 1999; 162:3625–3632
Kim KN, Watanabe S, Ma Y, et al. Viral IL-10 and soluble TNF receptor act synergistically to inhibit collagen-induced arthritis following adenovirus-mediated gene transfer. Journal of Immunology 2000; 164:1576–1581
Bessis N, Honiger J, Damotte D, et al. Encapsulation in hollow fibres of xenogeneic cells engineered to secrete IL-4 or IL-13 ameliorates murine collagen-induced arthritis (CIA). Clinical and Experimental Immunology 1999; 117:376–382
Chang Y, Prud'homme GJ. Intramuscular administration of expression plasmids encoding interferon-gamma receptor/IgG1 or IL-4/IgG1 chimeric proteins protects from autoimmunity. The Journal of Gene Medicine 1999; 1:415–423
Piccirillo CA, Prud'homme GJ. Prevention of experimental allergic encephalomyelitis by intramuscular gene transfer with cytokine-encoding plasmid vectors. Human Gene Therapy 1999; 10:1915–1922
Quattrocchi E, Walmsley M, Browne K, et al. Paradoxical effects of adenovirus-mediated blockade of TNF activity in murine collagen-induced arthritis. Journal of Immunology 1999; 163:1000–1009
Prud'homme GJ, Chang Y. Prevention of autoimmune diabetes by intramuscular gene therapy with a nonviral vector encoding an interferon-gamma receptor/IgG1 fusion protein. Gene Therapy 1999; 6:771–777
Lawson BR, Prud'homme GJ, Chang Y, et al. Treatment of murine lupus with cDNA encoding IFN-gammaR/Fc. The Journal of Clinical Investigation 2000; 106:207–215
Costa GL, Sandora MR, Nakajima A, et al. Adoptive immunotherapy of experimental autoimmune encephalomyelitis via T cell delivery of the IL-12 p40 subunit. Journal of Immunology 2001; 167:2379–2387
Lubberts E, Joosten LA, Chabaud M, et al. IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. The Journal of Clinical Investigation 2000; 105:1697–1710
Zhang HG, Fleck M, Kern ER, et al. Antigen presenting cells expressing Fas ligand down-modulate chronic inflammatory disease in Fas ligand-deficient mice. The Journal of Clinical Investigation 2000; 105:813–821
Tarner IH, Nakajima A, Seroogy CM, et al. Retroviral gene therapy of collagen-induced arthritis by local delivery of IL-4. Clinical Immunology (Orlando, Fla) 2002; 105:304–314
Smith R, Tarner IH, Hollenhorst M, et al. Localized expression of an anti-TNF single-chain antibody prevents development of collagen-induced arthritis. Gene Therapy 2003; 10: 1248–1257
Urbanek-Ruiz I, Ruiz PJ, Paragas V, et al. Immunization with DNA encoding an immunodominant peptide of insulin prevents diabetes in NOD mice. Clinical Immunology (Orlando, Fla) 2001; 100:164–171
Marson A, Kretschmer K, Frampton GM, et al. Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature 2007; 445:931–935.
Szanya V, Ermann J, Taylor C, Holness C, Fathman CG. The subpopulation of CD4+CD25+ splenocytes that delays adoptive transfer of diabetes expresses L-selectin and high levels of CCR7. Journal of Immunology 2002; 169:2461–2465
Ermann J, Hoffmann P, Edinger M, et al. Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. Blood 2005; 105:2220–2226
Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. The Journal of Experimental Medicine 2002; 196:389–399
Hanash AM, Levy RB. Donor CD4+CD25+ T cells promote engraftment and tolerance following MHC-mismatched hematopoietic cell transplantation. Blood 2005; 105: 1828–1836
Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nature Medicine 2003; 9:1144–1150
Trenado A, Charlotte F, Fisson S, et al. Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. The Journal of Clinical Investigation 2003; 112:1688–1696
Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002; 99:3493–3499
Godfrey WR, Ge YG, Spoden DJ, et al. In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures. Blood 2004; 104:453–461
Roncarolo MG, Bacchetta R, Bordignon C, Narula S, Levings MK. Type 1 T regulatory cells. Immunological Reviews 2001; 182:68–79
Tarbell KV, Yamazaki S, Olson K, Toy P, Steinman RM. CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. The Journal of Experimental Medicine 2004; 199:1467–1477
Maus MV, Thomas AK, Leonard DG, et al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nature Biotechnology 2002; 20:143–148
Dutt S, Ermann J, Tseng D, et al. L-selectin and beta7 integrin on donor CD4 T cells are required for the early migration to host mesenteric lymph nodes and acute colitis of graft-versus-host disease. Blood 2005; 106:4009–4015
Su L, Creusot RJ, Gallo EM, et al. Murine CD4+CD25+ regulatory T cells fail to undergo chromatin remodeling across the proximal promoter region of the IL-2 gene. Journal of Immunology 2004; 173:4994–5001
Sweeney TJ, Mailander V, Tucker AA, et al. Visualizing the kinetics of tumor-cell clearance in living animals. Proceedings of the National Academy of Sciences of the United States of America 1999; 96:12044–12049
Cao D, van Vollenhoven R, Klareskog L, Trollmo C, Malmstrom V. CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. Arthritis Research and Therapy 2004; 6:R335–R346
Beilhack A, Schulz S, Baker J, et al. In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets. Blood 2005; 106:1113–1122
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Acharya, S., Fathman, C.G. (2008). CD4+CD25+ Regulatory T Cells as Adoptive Cell Therapy for Autoimmune Disease and for the Treatment of Graft-Versus-Host Disease. In: Jiang, S. (eds) Regulatory T Cells and Clinical Application. Springer, New York, NY. https://doi.org/10.1007/978-0-387-77909-6_11
Download citation
DOI: https://doi.org/10.1007/978-0-387-77909-6_11
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-77908-9
Online ISBN: 978-0-387-77909-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)